Peter A. Thompson - Jun 14, 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Director
Signature: /s/ Maria Dobek, Attorney-in-Fact
Stock symbol: JANX
Transactions as of: Jun 14, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/16/2022, 04:35 PM
Previous filing: Jun 13, 2022
Next filing: Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock Option (right to buy)	Award	$0	+12.5K		$0.00	12.5K	Jun 14, 2022	Common Stock	12.5K	$10.73	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.
F2	Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.

Content

The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.